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TYPE OF DIABETES AND ADHERENCE TO 
SELF-MONITORING OF BLOOD GLUCOSE
(SMBG)
Vincze G, Barner JC, Lopez DA
University of Texas at Austin, Austin,TX, USA
OBJECTIVES: To assess the demographic, biological,
and psychosocial differences between type 1 and type 2
diabetics with respect to SMBG adherence. METHODS:
A self-administered questionnaire was used to collect
demographic (age, gender, income, race/ethnicity, educa-
tion, and marital status), biological (duration of diabetes,
comorbidities, health status, diabetes-related symptoms,
and Health care utilization) and psychosocial (physical
inﬂuence, self-efﬁcacy, outcome expectations, environ-
mental barriers, community resources, social support,
and insurance coverage) information as well as SMBG
adherence. Adherence was dichotomized using 80% as
the cut-off level. Diabetics from a county family clinic
completed the survey during several educational semi-
nars. T-test, Pearson’s chi-square and logistic regression
analyses were used and the level of statistical signiﬁcance
was set at .05. RESULTS: Most participants (n = 213)
were female (66.0%), with type 2 (77.1%) diabetes and
were 57.1 (SD: 12.5) years old. Adherence to SMBG was
signiﬁcantly higher among participants with type 1 com-
pared to participants with type 2 diabetes (68.4% (SD:
41.8) and 49.2% (SD: 40.3), respectively). Both sub-
groups perceived “environmental barriers” (e.g., incon-
venience, painfulness, and cost) as a signiﬁcant factor in
their adherence to SMBG. In addition, “physical inﬂu-
ence” (i.e., patients’ reliance on their diabetes symptoms
in determining when to monitor) and “comorbidities”
were signiﬁcantly and positively associated with adher-
ence to SMBG among participants with type 2 diabetes;
whereas, “insurance coverage” was signiﬁcantly and 
positively associated with adherence to SMBG among
participants with type 1 diabetes. CONCLUSIONS: As
expected, differences exist between type 1 and type 2 
diabetics in SMBG adherence. While “environmental 
barriers” was a signiﬁcant factor in both groups, “phys-
ical inﬂuence” and “comorbidities” were only associated
with SMBG adherence among type 2 diabetics; and
“insurance coverage” among type 1 diabetics. Providing
glucose-monitoring recommendations with the under-
standing of these differences may be important in achiev-
ing optimal patient adherence to SMBG.
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OBJECTIVE: To identify the costs and utility of sympto-
matic treatment using a shared model of care (SC) and
aggressive treatment using a hospital model of care (HT)
for established stable rheumatoid arthritis (duration >5
years) and estimate the relative cost acceptability of 
shared care. METHODS Data was obtained from 466
adults with established RA, who were enrolled into a 
randomised controlled trial of SC and HT and followed
for 36-months. A societal perspective was used; costs 
and outcomes were discounted at 3.5%, the recommended
UK Treasury rate. The primary outcome was quality
adjusted life years (QALY’s) measured by the EQ-5D 
questionnaire and population utility tariffs. Direct costs
were measured as resource use multiplied by published
national unit costs. An incremental cost utility ratio
(ICER) was estimated. Bootstrapping techniques were
used to derive net beneﬁt statistics and cost acceptability
curves and determine the probability that SC was cost
effective compared to HT. Sensitivity analysis was used to
assess the impact of alternative discount rates, alternative
methods of imputing missing and censored data and alter-
native sources of unit costs. RESULTS: SC is associated
with higher QALY’s and higher costs than HT, giving a
net cost of £1517/QALY gained. The probability that SC
was cost-effective was 0.89, over a £0 to £50,000 range
of cost/QALY threshold values. The probability that SC
was cost-effective ranged from 0.5 if decision makers are
prepared to pay £2000/QALY gained, to 0.8 for a thresh-
old of £13,000/QALY gained, to 0.9 for a threshold of
£42000/QALY gained. Sensitivity analysis showed that the
probability SC was cost effective was reduced if protocol
driven visits were included (p = 0.84) or censored data was
not imputed (p = 0.70). CONCLUSION: The primary and
sensitivity analyses indicate that shared care is likely to be
more cost-effective in the UK than hospital treatment in
70%-90% of cases.
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OBJECTIVES: To assess antiviral treatment (AVT) costs
associated with peginterferon alfa-2b plus ribavirin in
patients with chronic hepatitis C (CHC) in Germany.
Especially we focused on the impact of dose reduc-
tions/discontinuations, clinical management algorithms,
and future savings associated with the prevention of
advanced liver disease. METHODS: Clinical and drug
utilisation data were derived from a clinical trial (Manns,
